Use Of Oral Anticoagulation In A Real‐World Population With Device Detected Atrial Fibrillation

Researchers analyzed rates of oral anticoagulation (OAC) prescription in patients with device‐detected atrial fibrillation (AF) in this retrospective analysis in a large database of patients with cardiac implantable electronic devices. They joined data from the Optum de‐identified Electronic Health Record data set to the Medtronic CareLink database of cardiac implantable electronic devices. They calculated OAC prescription rates as a function of both AF duration and CHA2DS₂‐VASc score. Among 12,938 patients with device‐detected AF > 6 minutes, the overall OAC prescription rate was estimated to be 36.7%; it was found to be significantly elevated in those with a maximum daily AF duration > 23.5 hours (45.4%) vs those with 6 minutes to 23.5 hours (28.7%). Overall, findings revealed an increase in real‐world prescription of OAC in association with both increasing duration of AF and CHA2DS₂‐VASc score. This demonstrates the requirement for further inquiry into the role of AF duration, stroke risk, as well as the necessity for anticoagulation among patients with devices capable of long‐term AF monitoring.

​

Source